Numinus develops psilocybin-containing tea bag for use in psychedelic therapy

Numinus Wellness Inc. NUMI NUMIF, a mental health care company that specializes in innovative treatments and evidence-based psychedelic-assisted therapies, announced today that its research division, Numinus Bioscience, has developed a psilocybin-containing tea bag for use in clinical research and eventual treatment of clients in psychedelic-assisted therapy. Sharan Sidhu, Numinus VP, Scientific Research, Innovation Laboratory Operations, said the team developed the Psilocybe tea bag with scientific precision in mind. Our best-in-class team and resources allow us to control the full production process, from growth to finished product manufacturing, to deliver a product that is fully standardized. The tea bag was designed to use Numinus' validated strains of Psilocybe cubensis and develop processes and procedures to deliver 25 mg per dose.

The tea bag is being studied in a phase 1 trial of practitioners receiving experiential training for psilocybin-assisted therapy, with the goal to be used in Numinus' research, including trial partnerships with Cedar Clinical Research, Numinus' clinical trial management division, per a company press release.

The product has been submitted to Health Canada to be included on the psilocybin supplier list for the federal Special Access Program, through which health care providers can apply to provide psilocybin-assisted therapy, among other psychedelic-aided therapies, to patients with demonstrable needs.

Numinus is aware that solid therapeutic products, such as whole mushrooms or pills, may be unappealing or difficult to use by certain populations, such as some people receiving palliative care for serious illnesses, said Dr. Paul Thielking, Numinus chief science officer.

This new product is part of our commitment to increasing access to psychedelic-aided therapies for those in need, and contributes to the growing research that suggests psilocybin use in combination with therapy may be highly effective for treating mental health disorders, Thielking concluded.